Stryker Corporation

New York Stock Exchange
Back to all articles
Bearish -65

Stryker still working through cyberattack after-effects, stock down ...

AI-generated analysis

📉 SYK shares have plunged more than 10% in recent trading sessions following disclosures of ongoing supply disruptions linked to a prior cyberattack.

🏭 The peripheral vascular business, acquired via the $4.9 billion Inari Medical deal, is facing slower-than-expected recovery and integration challenges.

⚠️ CFO Preston Wells admitted that manufacturing was taken down for several weeks and that process improvements are still required to ramp up the peripheral side.

📅 Management has pushed the expected resolution of peripheral vascular business challenges from the third quarter to the fourth quarter of 2026.

💰 William Blair analysts estimate the integration setbacks could impact third-quarter sales by approximately $45 million, or 70-80 basis points.

🔒 The ongoing issues are directly attributed to an Iran-backed cyberattack that disrupted operations earlier in the year and slowed sales force execution.

Risk Factors
  • Stryker stock has declined more than 10% over the past five days as the company admits it is still managing significant supply disruptions.
  • The peripheral vascular business acquired from Inari Medical is not recovering as expected, requiring further process improvements and integration work.
  • CFO Preston Wells stated that manufacturing for the peripheral side was taken down for several weeks due to the cyberattack and has not fully returned to normal.
  • Analysts warn that the integration of the legacy Inari facility is taking longer than anticipated, creating incremental headwinds for the company.
  • Management has revised its guidance, now expecting to rectify peripheral vascular business challenges in the fourth quarter of 2026 instead of the previously stated third quarter.
  • William Blair analysts estimate a potential 70- to 80-basis-point impact to third-quarter sales, representing approximately $45 million in revenue loss.
Full Analysis
Stryker Corporation (NYSE: SYK) saw its stock price decline by more than 10% over the past five days as the company acknowledged ongoing supply disruptions affecting its operations. During a presentation at Wells Fargo's healthcare conference, CFO Preston Wells confirmed that the orthopedic and surgical device giant is still managing the aftermath of an Iran-backed cyberattack that occurred earlier in the year. The specific impact has been felt most acutely within the peripheral vascular business, which was acquired last year through the $4.9 billion purchase of Inari Medical. Management noted that while existing businesses have largely restarted processes, the integration of the legacy Inari manufacturing facility is taking longer than anticipated due to the cyber event's ripple effects on sales force execution and manufacturing ramp-up. CFO Wells revised the timeline for resolving these peripheral vascular challenges, stating that the company now expects to fully rectify the business issues by the fourth quarter of 2026, a delay from the previously stated third-quarter target. Analysts from William Blair estimate this integration setback could result in a potential 70- to 80-basis-point impact to third-quarter sales, translating to approximately $45 million in lost revenue based on their estimates. The company faces incremental headwinds as it works through the process of integrating manufacturing and scaling the peripheral side, which involves catheter-based mechanical thrombectomy devices. Management described the situation as a necessary but difficult process of restarting operations and improving processes over time to integrate the acquired facility into Stryker's broader system.